In other words, the nominal deal value of $40.5B (less than the $45B reported over the weekend) is 83% in cash and 17% in TEVA stock. TEVA is paying a steep price of 17x EBITDA for AGN’s generic-drug business.
After this transaction closes, AGN will have net debt close to zero, and it can thereby resume its aggressive acquisition of other brand-drug companies.
AGN's sale does not include the FoB program partnered with AMGN (#msg-70097496).
As a consequence of the TEVA-AGN deal, TEVA has dropped its hostile pursuit of MYL (who remains committed to its own hostile takeover of PRGO).
TEVA held a CC at 8am ET today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.